The Evolution of HTA in Emerging Markets Health-Care ... - TREE

More documents

Recommendations

Info

OHE Consulting Report for PhRMA 5 January 2011 saves input resources by assuming medicines are the same instead of exploring the appropriate use of different treatments in a given therapy area. This suggests that the industry be willing to support ‘efficient’ HTA, i.e. appropriate to a given country market and subject to the lessons we have set out above. 16
OHE Consulting Report for PhRMA 5 January 2011 2 Introduction and Context 2.1 Purpose of this report This project was commissioned by PhRMA to inform the development of policy positions with respect to the role (if any) for Health Technology Assessment (HTA) in emerging markets. PhRMA’s policy stance is not to promote the use of HTA where it doesn't exist but to be prepared with an appropriate response to engage and shape HTA when it is put forward by a payer. The purpose of the study is to help inform such an approach. This project was commissioned to inform the development of policy positions with respect to the role (if any) for Health Technology Assessment (HTA) in emerging markets, with a particular focus on Brazil, China and Taiwan. The term ‘emerging markets’ is generally applied to the set of countries that are experiencing rapid economic growth and/or a shift toward industrialisation. The definition of emerging markets is somewhat loose: it is used somewhat broadly to refer countries which are considered to be in a transitional phase between developing and developed status. The lack of a precise definition is reflected in the variation between the various classification systems that exist. For example, MSCI Barra list 21 economies as being emerging markets; and Dow Jones 35. FTSE distinguish between ‘Advanced’ and ‘Secondary’ emerging markets, on the basis of both their national income and the state of development of the economic infrastructure. Emerging markets, however defined, are of particular interest to the pharmaceutical industry. Most obviously, the increases in incomes in these countries mean they are becoming an important source of potential demand for pharmaceutical products. Economic growth in these countries is accompanied by changes in the way the economy is organised, and this typically extends to changes in arrangements about the way health care is financed, provided and regulated. Understanding the way in which these changes are likely to unfold, and the implications for market access and pricing of pharmaceuticals, is of key interest to industry. 2.2 Structure of this Report This report is structured as follows: Section 2 recaps the Terms of Reference for the project Section 3 sets out the approach we are taking Section 4 seeks to categorise the development of health care systems Section 5 looks at the evolution of HTA Section 6 links together HTA and health care systems Section 7 describes the main results from our review of the health care systems and use of HTA in Brazil, China and Taiwan 17
Page 1 and 2: Consulting Report 1 The Evolution
Page 3 and 4: OHE Consulting Report for PhRMA 5 J
Page 15: OHE Consulting Report for PhRMA 5 J
Page 67 and 68:
OHE Consulting Report for PhRMA 5 J
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119:
show all

The Evolution of HTA in Emerging Markets Health-Care ... - TREE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?